<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>18</Volume>
				<Issue>3</Issue>
				<PubDate PubStatus="epublish">
					<Year>2017</Year>
					<Month>03</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>The Meningioma 1 (MN1) Gene is an Independent Poor Prognostic Factor in Adult Egyptian Acute Myeloid Leukemia Patients</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>609</FirstPage>
			<LastPage>613</LastPage>
			<ELocationID EIdType="pii">44745</ELocationID>
			
<ELocationID EIdType="doi">10.22034/APJCP.2017.18.3.609</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Roxan </FirstName>
					<LastName>Shafik</LastName>
<Affiliation>National Cancer Institute, Cairo University, Medical Oncology Department, Egypt</Affiliation>
<Identifier Source="ORCID">0000-0002-7403-839x</Identifier>

</Author>
<Author>
					<FirstName>Naglaa </FirstName>
					<LastName>Hassan</LastName>
<Affiliation>National Cancer Institute, Cairo University, Medical Oncology Department, Egypt</Affiliation>
<Identifier Source="ORCID">0000-0002-3195-1568</Identifier>

</Author>
<Author>
					<FirstName>Yomna </FirstName>
					<LastName>El-Meligui</LastName>
<Affiliation>National Cancer Institute, Cairo University, Medical Oncology Department, Egypt</Affiliation>

</Author>
<Author>
					<FirstName>Hanan </FirstName>
					<LastName>Shafik</LastName>
<Affiliation>National Cancer Institute, Cairo University, Medical Oncology Department, Egypt</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2016</Year>
					<Month>11</Month>
					<Day>06</Day>
				</PubDate>
			</History>
		<Abstract> &lt;br /&gt; &lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Aim: &lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;To determine the prognostic importance of meningioma 1 (MN1) gene expression levels in the context of other predictive markers for acute myeloid leukemia (AML) cases. &lt;/span&gt;&lt;/span&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Methods: &lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;MN1 expression was measured in 85 newly diagnosed adults younger than 60 years by real-time reverse-transcriptase polymerase chain reaction. &lt;/span&gt;&lt;/span&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Results: &lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;At diagnosis 67.4% of cases had elevated MN1 expression, this being associated with a worse prognosis, higher incidence of lymphadenopathy and CD34 transcript expression (p=0.02 and &lt;0.001, respectively). No other molecular or clinical &lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;characteristics were significantly associated with MN1expression. Patients with high MN1 expression had lower complete response rate at day 15 compared to patients with low MN1 expression (p=0.09) and a signi&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-size: small;&quot;&gt;fi&lt;/span&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;cantly higher &lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;relapse rate (21.1% versus 7.7%, respectively, p=0.04). Patients with high MN1 expression had shorter TTP compared to those with low expression, p= 0.07. &lt;/span&gt;&lt;/span&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Conclusion: &lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;MN1 expression may predict outcome in AML patients. The MN1 gene and micro RNA expression suggest a biological feature that could be used as therapeutic targets. &lt;/span&gt;&lt;/span&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Key words: MN1 gene</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">AML</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Prognostic factors</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_44745_8f9e7c493c9fa2b2081cdbff43182aa3.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
